Table 1 Demographic and disease characteristics of the study cohort
Frequency (n) | Percentage | |
|---|---|---|
Sample size | 68 | |
Gender | ||
Female | 54 | 79.4% |
Male | 14 | 20.6% |
Race/Ethnicity | ||
White | 48 | 70.6% |
Hispanic | 10 | 14.7% |
African American | 6 | 8.8% |
Others | 4 | 5.9% |
Age | ||
Less than 5 years | 26 | 38.2% |
More than 5 years | 42 | 61.8% |
Treatment status at 1st visit | ||
Untreated | 36 | 52.9% |
Treated | 32 | 47.1% |
Myositis specific antibodies | ||
P155/140 | 29 | 42.6% |
MJ | 5 | 7.2% |
Mi2 | 5 | 7.2% |
MDA5 | 2 | 2.9% |
Others or multiple MSAs | 1 | 1.5% |
Negative | 26 | 38.2% |
Treatment | ||
Oral steroid | 68 | 100% |
Intravenous steroid | 60 | 88.2% |
Methotrexate | 66 | 97.1% |
Intravenous immunoglobulin | 14 | 20.6% |
Hydroxychloroquine | 28 | 41.2% |
Cyclosporin | 19 | 27.9% |
Mycophenolate | 43 | 63.2% |